Central Trust Co (CTTC) 0.1900 $CTTC
Conrad F. Mir, CEO of Competitive Technologies (OTCQX: CTTC) to Be Interviewed LIVE on Clear Channel Business Talk Radio -- August 14th, 2014
Marketwire - Wed Aug 13, 6:15AM CDT
Competitive Technologies, Inc (OTCQX: CTTC) (CTI) announced today that Chief Executive Officer (CEO) Conrad F. Mir will be interviewed live tomorrow by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network Show. Mr. Mir will be discussing Competitive Technologies Inc., the pain mitigation company, which develops and commercializes innovative pain management products and technologies. CTI holds the 510k clearance on its flagship product, the non-invasive Calmare(R) Pain Therapy Device. CTI is the exclusive licensed global distributor of Calmare.
Competitive Tech Brings Sales Management Position In-house
PR Newswire - Mon Aug 11, 1:22PM CDT
Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), names William Lipford, the current Midwest Regional Sales Manager for CTI, U.S. division head of product sales. In his new role, he will be responsible to direct all U.S. sales of CTI's flagship product, the Calmare® Pain Therapy device, and oversee the expansion of CTI's independent, distributor sales force across the United States.
SeeThruEquity Initiates Coverage on Competitive Technologies (OTCQX:CTTC) with a Speculative Buy Rating - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Thu Jul 03, 9:36AM CDT
Vancouver, BC, July 3, 2014 - New York-based SeeThruEquity has initiated coverage on Competitive Technologies (OTCQX:CTTC). Analyst Brandon Primack gives the company a speculative buy rating, and a target price of $0.79, a premium of 147% to the $0.32 price on June 26th, the day the report was issued.
Judge Ruling Favors Calmare® Pain Therapy Reimbursement In Personal Injury Case Against Allstate Insurance Co.
PR Newswire - Mon Jun 30, 8:32AM CDT
The Calmare® Pain Therapy Device, the flagship product of Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), the pain mitigation company, gained a favorable reimbursement ruling from the New York City Civil Courts in a personal injury case against Allstate Insurance, Co., (Allstate). In the ruling, the Court instructed the insurance giant to reimburse Forest Rehabilitation Medicine P.C. (Forest) for its use of Calmare pain therapy (Calmare) on patients who suffer pain as a result of car accident injuries.
SeeThruEquity Initiates Research Coverage on Competitive Technologies Inc. with Target Price of $0.79
ACCESSWIRE - Thu Jun 26, 8:02AM CDT
New York, NY / ACCESSWIRE / June 26, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Competitive Technologies Inc. (OTCQX: CTTC), a pain mitigation company with innovative wound and pain management products and technologies.
Competitive Tech To Sell Into Europe, The Middle East And North Africa
PR Newswire - Wed Apr 02, 9:15AM CDT
Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), a pain mitigation company, will sell into Europe, the Middle East and North Africa (the "EMENA territory"
effective immediately, in an effort to reestablish the global footprint that was compromised by the signing of the 2012 Amended Distribution and Sales Agreement (the "Amendment" between the inventor and the Company.
East Idaho Interventional Pain Center Now Offering The Calmare® Pain Therapy Device Treatments
PR Newswire - Thu Mar 27, 9:58AM CDT
Patients living with chronic neuropathic and oncologic pain in the Idaho Falls region can now count on a new arsenal in the fight against these conditions. The medical team at East Idaho Interventional Pain Center is now offering a non-invasive approach to their patients with the addition of the Calmare® Pain Therapy Device treatments as part of the suite of procedures offered at the center.
New Study Results: Calmare® Pain Device Therapy May Reduce Chemotherapy-Induced Pain Scores By About 30%
PR Newswire - Tue Mar 25, 9:30AM CDT
The results of a recently published, single-arm clinical study in the Journal of Pain and Palliative Care Pharmacotherapy, (December 2013) demonstrated how a cohort of 39 chronic, chemotherapy- induced peripheral neuropathy (CIPN) patients experienced an average pain score reduction of 31.8% in their level of chronic pain undergoing Calmare® Pain Device therapy - Competitive Technologies, Inc., (OTCQX: CTTC) (CTI) flagship medical product.
Competitive Tech Names Former "Big Pharma" Sales Executive U.S. Division Head of Product Sales
PR Newswire - Wed Mar 05, 8:14AM CST
Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), names Joel Bradus, former "Big Pharma" sales executive, U.S. division head of product sales. Mr. Bradus was appointed with the full responsibility of steering and expanding the Calmare products sales force in the United States.
Pipeline Mosque Inaugurates Africell-Sponsored Minaret
All Africa Global Media - Tue Feb 25, 11:05AM CST
The Pipeline Mosque on Friday inaugurated its new 33.35 meters minaret, reportedly sponsored by Africell GSM Company to the tune of D1 million.
Noka Resources Closes Oversubscribed Second Tranche of Financing
Marketwire - Tue Feb 25, 8:05AM CST
Noka Resources Inc. (TSX VENTURE: NX)(FRANKFURT: 2NK) (the "Company" is pleased to announce that, further to the Company's news release dated February 6, 2014 whereas the Company closed $597,500 of the Non-Brokered Private Placement financing (the "Financing" , the Company has closed the second tranche of the Financing for additional gross proceeds of $536,000, bringing the total amount raised to $1,133,500.
Competitive Tech Slated To Present At The See Thru Equity Winter Microcap Investor Conference
PR Newswire - Wed Feb 05, 2:25PM CST
Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), the pain mitigation company, is slated to present at the SeeThruEquity Winter Microcap Investor Conference on Thursday, February 6, 2014, at 1:30 PM EST.
WNS (Holdings) Beats Fiscal Q3 Earnings, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 1:10PM CST
WNS (Holdings) reported operating net earnings of 38 cents per share for fiscal third-quarter 2014 ending Dec 31, 2013, beating the Zacks Consensus Estimate.
Competitive Tech's Calmare® Pain Device Therapy Garners Favorable Medicare Coverage Judgment
PR Newswire - Wed Jan 15, 9:35AM CST
Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), a biotechnology company, received a favorable Medicare treatment coverage judgment for its flagship medical technology device, the Calmare® pain therapy medical device, stemming from an appeal filed by an authorized Calmare practitioner in Staten Island, the Physical Medicine and Rehabilitation Associates of Staten Island, LLP (collectively, the Calmare Pain Relief Solutions or CPRS), by and through, Christopher M. Perez, M.D. U.S. Administrative Law Judge LeAnn R. Canter allowed the appeal, which resolved claims for Medicare coverage for a named Medicare enrollee (Beneficiary). The appeal allows CPRS to receive reimbursements for treatments using the Calmare Therapy for claims made in behalf of beneficiary.
Competitive Technologies Announces Financial Results for the Six Months Ended June 30, 2013
GlobeNewswire - Tue Aug 13, 1:14PM CDT
Competitive Technologies, Inc. (OTCQX:CTTC) announced today its financial results for the six months ended June 30, 2013. Revenues for the first half of 2013 were $0.2 million and expenses were $1.7 million producing a net loss for the first half of 2013 of $1.5 million.
Forest Rehabilitation Medicine PC Opens Sixth Clinic Utilizing Calmare/Scrambler Chronic Pain Therapy on Staten Island and Brooklyn
Marketwire - Thu Jun 27, 7:33AM CDT
Forest Rehabilitation Medicine PC a chronic pain treatment medical practice with multiple locations on Staten Island and now in Brooklyn, announced today the opening of its sixth clinic at the offices of Daniel W. Wilen, MD, Board-certified Orthopedic Surgeon, at 9202 Fort Hamilton Parkway, Brooklyn, New York 11209, using Calmare/Scrambler Therapy, a non-invasive and non-narcotic therapy for the treatment of chronic neuropathic pain.
Competitive Technologies, Inc. Announces Sales of Its Calmare(R) Pain Therapy Medical Device
GlobeNewswire - Tue Jun 25, 9:43AM CDT
Competitive Technologies, Inc. (OTCQX:CTTC) today announced two recent sales of Calmare medical devices, one to a military hospital and one to a physician practice, both located in the Northwest region of the United States.
Competitive Technologies Shareholders Elected Directors at Annual Shareholder Meeting
GlobeNewswire - Thu Jun 20, 10:44AM CDT
Competitive Technologies Inc. (OTCQX:CTTC) held its annual meeting of shareholders earlier today at the Norwalk Inn and Conference Center in Norwalk, Conn. CTTC's Chairman, Peter Brennan conducted the business meeting and President and Chief Executive Officer, Carl O'Connell, provided an overview of the Company's plans.
Competitive Technologies, Inc. Announces Presentation at American Urological Association
GlobeNewswire - Wed Jun 19, 2:49PM CDT
Competitive Technologies, Inc. (OTCQX:CTTC) today announced an update regarding Xion Pharmaceuticals ("Xion" , a joint venture with CTTC formed in 2010 to advance the commercialization of Melanotan-II (MT-II) peptides especially for sexual dysfunction.
Competitive Technologies Announces Financial Results for Quarter Ended March 31, 2013
GlobeNewswire - Wed Jun 19, 1:16PM CDT
Competitive Technologies, Inc. (OTCQX:CTTC) announced today its financial results for the first quarter 2013. Revenues for the quarter were $0.06 million and expenses were $0.8 million producing a net loss for the quarter of $0.8 million.
Conrad F. Mir, CEO of Competitive Technologies (OTCQX: CTTC) to Be Interviewed LIVE on Clear Channel Business Talk Radio -- August 14th, 2014
Marketwire - Wed Aug 13, 6:15AM CDT
Competitive Technologies, Inc (OTCQX: CTTC) (CTI) announced today that Chief Executive Officer (CEO) Conrad F. Mir will be interviewed live tomorrow by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network Show. Mr. Mir will be discussing Competitive Technologies Inc., the pain mitigation company, which develops and commercializes innovative pain management products and technologies. CTI holds the 510k clearance on its flagship product, the non-invasive Calmare(R) Pain Therapy Device. CTI is the exclusive licensed global distributor of Calmare.
Competitive Tech Brings Sales Management Position In-house
PR Newswire - Mon Aug 11, 1:22PM CDT
Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), names William Lipford, the current Midwest Regional Sales Manager for CTI, U.S. division head of product sales. In his new role, he will be responsible to direct all U.S. sales of CTI's flagship product, the Calmare® Pain Therapy device, and oversee the expansion of CTI's independent, distributor sales force across the United States.
SeeThruEquity Initiates Coverage on Competitive Technologies (OTCQX:CTTC) with a Speculative Buy Rating - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Thu Jul 03, 9:36AM CDT
Vancouver, BC, July 3, 2014 - New York-based SeeThruEquity has initiated coverage on Competitive Technologies (OTCQX:CTTC). Analyst Brandon Primack gives the company a speculative buy rating, and a target price of $0.79, a premium of 147% to the $0.32 price on June 26th, the day the report was issued.
Judge Ruling Favors Calmare® Pain Therapy Reimbursement In Personal Injury Case Against Allstate Insurance Co.
PR Newswire - Mon Jun 30, 8:32AM CDT
The Calmare® Pain Therapy Device, the flagship product of Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), the pain mitigation company, gained a favorable reimbursement ruling from the New York City Civil Courts in a personal injury case against Allstate Insurance, Co., (Allstate). In the ruling, the Court instructed the insurance giant to reimburse Forest Rehabilitation Medicine P.C. (Forest) for its use of Calmare pain therapy (Calmare) on patients who suffer pain as a result of car accident injuries.
SeeThruEquity Initiates Research Coverage on Competitive Technologies Inc. with Target Price of $0.79
ACCESSWIRE - Thu Jun 26, 8:02AM CDT
New York, NY / ACCESSWIRE / June 26, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Competitive Technologies Inc. (OTCQX: CTTC), a pain mitigation company with innovative wound and pain management products and technologies.
Competitive Tech To Sell Into Europe, The Middle East And North Africa
PR Newswire - Wed Apr 02, 9:15AM CDT
Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), a pain mitigation company, will sell into Europe, the Middle East and North Africa (the "EMENA territory"
effective immediately, in an effort to reestablish the global footprint that was compromised by the signing of the 2012 Amended Distribution and Sales Agreement (the "Amendment" between the inventor and the Company. East Idaho Interventional Pain Center Now Offering The Calmare® Pain Therapy Device Treatments
PR Newswire - Thu Mar 27, 9:58AM CDT
Patients living with chronic neuropathic and oncologic pain in the Idaho Falls region can now count on a new arsenal in the fight against these conditions. The medical team at East Idaho Interventional Pain Center is now offering a non-invasive approach to their patients with the addition of the Calmare® Pain Therapy Device treatments as part of the suite of procedures offered at the center.
New Study Results: Calmare® Pain Device Therapy May Reduce Chemotherapy-Induced Pain Scores By About 30%
PR Newswire - Tue Mar 25, 9:30AM CDT
The results of a recently published, single-arm clinical study in the Journal of Pain and Palliative Care Pharmacotherapy, (December 2013) demonstrated how a cohort of 39 chronic, chemotherapy- induced peripheral neuropathy (CIPN) patients experienced an average pain score reduction of 31.8% in their level of chronic pain undergoing Calmare® Pain Device therapy - Competitive Technologies, Inc., (OTCQX: CTTC) (CTI) flagship medical product.
Competitive Tech Names Former "Big Pharma" Sales Executive U.S. Division Head of Product Sales
PR Newswire - Wed Mar 05, 8:14AM CST
Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), names Joel Bradus, former "Big Pharma" sales executive, U.S. division head of product sales. Mr. Bradus was appointed with the full responsibility of steering and expanding the Calmare products sales force in the United States.
Pipeline Mosque Inaugurates Africell-Sponsored Minaret
All Africa Global Media - Tue Feb 25, 11:05AM CST
The Pipeline Mosque on Friday inaugurated its new 33.35 meters minaret, reportedly sponsored by Africell GSM Company to the tune of D1 million.
Noka Resources Closes Oversubscribed Second Tranche of Financing
Marketwire - Tue Feb 25, 8:05AM CST
Noka Resources Inc. (TSX VENTURE: NX)(FRANKFURT: 2NK) (the "Company"
is pleased to announce that, further to the Company's news release dated February 6, 2014 whereas the Company closed $597,500 of the Non-Brokered Private Placement financing (the "Financing" , the Company has closed the second tranche of the Financing for additional gross proceeds of $536,000, bringing the total amount raised to $1,133,500. Competitive Tech Slated To Present At The See Thru Equity Winter Microcap Investor Conference
PR Newswire - Wed Feb 05, 2:25PM CST
Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), the pain mitigation company, is slated to present at the SeeThruEquity Winter Microcap Investor Conference on Thursday, February 6, 2014, at 1:30 PM EST.
WNS (Holdings) Beats Fiscal Q3 Earnings, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 1:10PM CST
WNS (Holdings) reported operating net earnings of 38 cents per share for fiscal third-quarter 2014 ending Dec 31, 2013, beating the Zacks Consensus Estimate.
Competitive Tech's Calmare® Pain Device Therapy Garners Favorable Medicare Coverage Judgment
PR Newswire - Wed Jan 15, 9:35AM CST
Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), a biotechnology company, received a favorable Medicare treatment coverage judgment for its flagship medical technology device, the Calmare® pain therapy medical device, stemming from an appeal filed by an authorized Calmare practitioner in Staten Island, the Physical Medicine and Rehabilitation Associates of Staten Island, LLP (collectively, the Calmare Pain Relief Solutions or CPRS), by and through, Christopher M. Perez, M.D. U.S. Administrative Law Judge LeAnn R. Canter allowed the appeal, which resolved claims for Medicare coverage for a named Medicare enrollee (Beneficiary). The appeal allows CPRS to receive reimbursements for treatments using the Calmare Therapy for claims made in behalf of beneficiary.
Competitive Technologies Announces Financial Results for the Six Months Ended June 30, 2013
GlobeNewswire - Tue Aug 13, 1:14PM CDT
Competitive Technologies, Inc. (OTCQX:CTTC) announced today its financial results for the six months ended June 30, 2013. Revenues for the first half of 2013 were $0.2 million and expenses were $1.7 million producing a net loss for the first half of 2013 of $1.5 million.
Forest Rehabilitation Medicine PC Opens Sixth Clinic Utilizing Calmare/Scrambler Chronic Pain Therapy on Staten Island and Brooklyn
Marketwire - Thu Jun 27, 7:33AM CDT
Forest Rehabilitation Medicine PC a chronic pain treatment medical practice with multiple locations on Staten Island and now in Brooklyn, announced today the opening of its sixth clinic at the offices of Daniel W. Wilen, MD, Board-certified Orthopedic Surgeon, at 9202 Fort Hamilton Parkway, Brooklyn, New York 11209, using Calmare/Scrambler Therapy, a non-invasive and non-narcotic therapy for the treatment of chronic neuropathic pain.
Competitive Technologies, Inc. Announces Sales of Its Calmare(R) Pain Therapy Medical Device
GlobeNewswire - Tue Jun 25, 9:43AM CDT
Competitive Technologies, Inc. (OTCQX:CTTC) today announced two recent sales of Calmare medical devices, one to a military hospital and one to a physician practice, both located in the Northwest region of the United States.
Competitive Technologies Shareholders Elected Directors at Annual Shareholder Meeting
GlobeNewswire - Thu Jun 20, 10:44AM CDT
Competitive Technologies Inc. (OTCQX:CTTC) held its annual meeting of shareholders earlier today at the Norwalk Inn and Conference Center in Norwalk, Conn. CTTC's Chairman, Peter Brennan conducted the business meeting and President and Chief Executive Officer, Carl O'Connell, provided an overview of the Company's plans.
Competitive Technologies, Inc. Announces Presentation at American Urological Association
GlobeNewswire - Wed Jun 19, 2:49PM CDT
Competitive Technologies, Inc. (OTCQX:CTTC) today announced an update regarding Xion Pharmaceuticals ("Xion"
, a joint venture with CTTC formed in 2010 to advance the commercialization of Melanotan-II (MT-II) peptides especially for sexual dysfunction. Competitive Technologies Announces Financial Results for Quarter Ended March 31, 2013
GlobeNewswire - Wed Jun 19, 1:16PM CDT
Competitive Technologies, Inc. (OTCQX:CTTC) announced today its financial results for the first quarter 2013. Revenues for the quarter were $0.06 million and expenses were $0.8 million producing a net loss for the quarter of $0.8 million.
